Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration (nAMD)
Phase 1
Active, not recruiting
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Drug: AXT107 Low DoseDrug: AXT107 Mid DoseDrug: AXT107 High Dose
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- AsclepiX Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT05859776
- Locations
- ๐บ๐ธ
Erie Retina Research, Erie, Pennsylvania, United States
๐บ๐ธNew England Retina Consultants, Springfield, Massachusetts, United States
๐บ๐ธThe Retina Institue, Saint Louis, Missouri, United States
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
Phase 1
Terminated
- Conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Interventions
- Drug: AXT107 0.1 mgDrug: AXT107 0.5 mgDrug: AXT107 0.25 mg
- First Posted Date
- 2021-02-10
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- AsclepiX Therapeutics, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT04746963
- Locations
- ๐บ๐ธ
AsclepiX Investigative Site, The Woodlands, Texas, United States
Safety and Bioactivity of AXT107 in Subjects With Diabetic Macular Edema
Phase 1
Terminated
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- Drug: AXT107 0.25 mgDrug: AXT107 0.5 mgDrug: AXT107 0.1 mg
- First Posted Date
- 2021-01-06
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- AsclepiX Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04697758
- Locations
- ๐บ๐ธ
AsclepiX Investigative Site, The Woodlands, Texas, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath